Amyloid beta 42 alters cardiac metabolism and impairs cardiac function in male mice with obesity

Liam G. Hall, Juliane K. Czeczor, Timothy Connor, Javier Botella, Kirstie A. Jong, Mark C. Renton, Amanda J. Genders, Kylie Venardos, Sheree D. Martin, Simon T. Bond, Kathryn Aston-Mourney, Kirsten F. Howlett, James A. Campbell, Greg R. Collier, Ken R. Walder, Matthew McKenzie, Mark Ziemann and Sean L. McGee ()
Additional contact information
Liam G. Hall: Deakin University
Juliane K. Czeczor: Deakin University
Timothy Connor: Deakin University
Javier Botella: Deakin University
Kirstie A. Jong: Deakin University
Mark C. Renton: Deakin University
Amanda J. Genders: Deakin University
Kylie Venardos: Deakin University
Sheree D. Martin: Deakin University
Simon T. Bond: Deakin University
Kathryn Aston-Mourney: Deakin University
Kirsten F. Howlett: Deakin University
James A. Campbell: Ambetex Pty Ltd
Greg R. Collier: Ambetex Pty Ltd
Ken R. Walder: Deakin University
Matthew McKenzie: Deakin University
Mark Ziemann: Deakin University
Sean L. McGee: Deakin University

Nature Communications, 2024, vol. 15, issue 1, 1-13

Abstract: Abstract There are epidemiological associations between obesity and type 2 diabetes, cardiovascular disease and Alzheimer’s disease. The role of amyloid beta 42 (Aβ42) in these diverse chronic diseases is obscure. Here we show that adipose tissue releases Aβ42, which is increased from adipose tissue of male mice with obesity and is associated with higher plasma Aβ42. Increasing circulating Aβ42 levels in male mice without obesity has no effect on systemic glucose homeostasis but has obesity-like effects on the heart, including reduced cardiac glucose clearance and impaired cardiac function. The closely related Aβ40 isoform does not have these same effects on the heart. Administration of an Aβ-neutralising antibody prevents obesity-induced cardiac dysfunction and hypertrophy. Furthermore, Aβ-neutralising antibody administration in established obesity prevents further deterioration of cardiac function. Multi-contrast transcriptomic analyses reveal that Aβ42 impacts pathways of mitochondrial metabolism and exposure of cardiomyocytes to Aβ42 inhibits mitochondrial complex I. These data reveal a role for systemic Aβ42 in the development of cardiac disease in obesity and suggest that therapeutics designed for Alzheimer’s disease could be effective in combating obesity-induced heart failure.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-44520-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-023-44520-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-44520-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().